Migraine Drugs Market Research Report - Global Forecast till 2027

Global Migraine Drugs Market Research Report: By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices), By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2027

ID: MRFR/HC/6907-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Forecast


Global Migraine Drugs Market is expected to hold a value of USD 6.5 Billion by 2025 at a CAGR of 5.9%.


Migraine Drugs Market Synopsis


Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in hormone levels. As of 2018, approximately 14.5% world’s population was suffering from different types of migraines, and 2% of the world’s population was suffering from chronic migraines.  


The treatment of migraine headaches is eased by the administration of preventive medications, to avoid the migraine attacks and abortive medications to relieve the strong and periodic pain.


Migraine Drugs Market Influencer


The increasing prevalence of migraine is expected to contribute to the growth of the migraine drugs market during the forecast period.


Market Drivers



  • Increasing prevalence of migraine worldwide. As of January 2019, 2.9% of the deaths occurred due to migraine worldwide.

  • Rapidly changing lifestyle

  • Growing awareness programs regarding the prevention and treatment of migraine

  • Rising R&D investment for the development of innovative drugs for the treatment of migraine

  • Increased uptake of novel drug classes and the introduction of peptide-based therapies for the treatment of migraine


Market Restraints



  • Stringent government regulations

  • High investment required for drug research and development

  • Side-effects of medications prescribed for migraine


Global Migraine Drugs Market Segmentation


By Type



  • Episodic Migraine: It is characterized by patients with migraine who have 0 to 14 headache days per month. This segment holds the highest share in the market.

  • Chronic Migraine: It is characterized by patients with migraine who have 15 or more headache days per month. This segment is expected to grow faster during the forecast period. Chronic migraine affected approximately 2% of the global population.


By Treatment type



  • Acute: It is the largest segment. It represents approximately 90% of the share in the market. This segment is expected to register a CAGR of 6.1% during the forecast period. All the patients suffering from migraine require acute therapy, regardless of whether they are also treated with preventative therapy. In addition to this, acute treatments are also used in combination with preventive treatments. Major companies in the market are conducting R&D of novel acute therapeutics, and it is expected that 5 to 8 major drugs will be launched that will boost the market during the forecast period.

  • Preventive: It is the second-largest segment in the market. It holds 8% share in the market. Preventative treatments reduce frequency and disability of migraine. The major drugs classes included in preventive treatments are beta-blockers, botulin toxins, and topiramate.

  • Neuromodulation Devices: It is the fastest segment in the market. It holds approximately 2% share in the market. There are three major FDA approved neuromodulation devices for the treatment of migraine in the US market.  


By Drug Class



  • Triptans: It holds the highest share in the market. It is used in the acute treatment of migraine.

  • Betablockers: These are majorly used in the preventive migraine therapeutics.

  • Angiotensin Blockers: These are used as preventive headache treatments for chronic migraine.

  • Tricyclics: These are used as preventive headache treatments for chronic migraine. Tricyclic antidepressants (TCAs) are the first agents shown to be effective in the prophylaxis of migraine.

  • Anticonvulsants: These drugs prevent seizures, headaches, and acute migraines. Topiramate (Qudexy XR, Topamax) and valproic acid (Depakene, Depakote) anticonvulsants are used for the treatment of acute migraine


By End-User



  • Hospitals and Clinics: The largest segment. Hospitals and clinics are the primary points of care for the treatment of migraine. Rising prevalence of migraine is expected to drive the market growth.

  • Retail Pharmacy: It is the second largest segment and provides prescribed migraine drugs for chronic migraine conditions and over the counter migraine drugs for acute migraine conditions.

  • Online Pharmacy: It is the fastest-growing segment which provides migraine drugs through e-commerce platforms. The drug class majorly offered by online pharmacy chains are for acute migraine treatment

  • Others: This segment includes centers for home care and elderly population.


By Region



  • Americas: The largest regional market. The prevalence of migraine is high in the Americas. Approximately, 12% of the US population including 18% of women, 6% of men, and 10% of the children were suffering from different types of migraines in the US as of December 2018. Moreover, the healthcare infrastructure in the Americas is also developed, which contributes to market growth. Furthermore, major pharmaceutical companies such as Pfizer Inc. and Alder Biopharmaceuticals, Inc. are headquartered in the US, which positively contributes to the growth of the migraine drugs market in the Americas.



  • Europe: An increasing prevalence of neurological diseases including migraine in major countries such as the UK, Germany, France, Italy, Spain, and Russia, increasing healthcare expenditure, availability of funds for research, and rising R&D investment for the development of innovative drugs for migraine are anticipated to drive the market growth in Europe. Approximately 1 in 7 people in the UK experience migraine. It also stated that there are around 190,000 migraine attacks in the UK as of December 2018.



  • Asia-Pacific: The fastest-growing regional market. Asia-Pacific is seeing a surge in the number of people suffering from migraine. Moreover, government and non-government organizations are conducting awareness programs for migraine, which is expected to drive the market growth.



  • Middle East & Africa: The market is expected to show significant growth due to the rising patient population suffering from migraine. The market in the Middle East is expected to show more growth as compared to the African market owing to fast-developing healthcare facilities in the Middle Eastern countries such as Saudi Arabia, Qatar, and Oman.


Migraine Drugs Market Key Players



  • Allergan Plc (Ireland)

  • Alder Biopharmaceuticals, Inc. (US)

  • Pfizer Inc. (US)

  • GlaxoSmithKline Plc (UK)

  • Merck & Co., Inc. (US)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • AstraZeneca PLC (UK)

  • Johnson & Johnson Services, Inc. (US)

  • Amgen Inc. (US)

  • Eli Lilly and Company

  • eNeura Inc.



Frequently Asked Questions (FAQ) :


The global migraine drugs market is projected to reach a valuation of USD 6.5 BN by 2025.

The global migraine drugs market is projected to grow at approximately 5.9% CAGR during forecast period (2019-2025).

Rising R&D investments for the innovative drug discoveries for the treatment of the condition.

North America holds the largest share in the global migraine drugs market, followed by Europe and the Asia Pacific, respectively.

Alder Biopharmaceuticals, Inc. (US), Allergan Plc (Ireland), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline Plc (UK), Teva Pharmaceutical Industries Ltd (Israel), Johnson & Johnson Services, Inc. (US), AstraZeneca PLC (UK), Amgen Inc. (US), and Eli Lilly and Company eNeura Inc., are some of the major players operating in the migraine drugs market.



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.